Alumis Inc.
ALMS
Kedudukan dalam Saham
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.15
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$795.38M
Perubahan (1 hari)
-2.61%
Perubahan (1 tahun)
170.70%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
EPS untuk Alumis Inc. (ALMS)
EPS setakat March 2025 TTM: $-2.70
Menurut laporan kewangan terkini dan harga saham Alumis Inc., EPS semasa syarikat (TTM) adalah $-2.70. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-5.43 peningkatan berbanding EPS tahun 2022 iaitu $-0.70.
Sejarah EPS untuk Alumis Inc. dari 2021 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
